Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Next Previous
Trial Profile

Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apinocaltamide (Primary)
  • Indications Encephalopathy; Epilepsy
  • Focus Adverse reactions
  • Acronyms Steamboat 2
  • Sponsors Neurocrine Biosciences

Most Recent Events

  • 28 Feb 2025 Status changed from active, no longer recruiting to discontinued.
  • 18 Oct 2024 Status changed from recruiting to active, no longer recruiting.
  • 17 Aug 2023 Upper age limit for the inclusion criteria is decreased from 17 to 12 years and timeline for primary end-point is changed from 242 weeks to 238 weeks.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top